Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia

Cerebellum

Volumn 10, Issue 1, 2011, Pages 1-8

  Velasco Sánchez, Daniel ^a,b   Aracil, Asuncion ^a   Montero, Raquel ^c   Mas, Ana ^a   Jiménez, Lorenzo ^a   O'Callaghan, Mar ^a   Tondo, Maria ^c   Capdevila, Antoni ^a   Blanch, Josep ^a   Artuch, Rafael ^c   Pineda, Mercedes ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Fundacion Sant Joan de Deu   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Deferiprone; Friedreich's ataxia; Idebenone; Iron chelator

Indexed keywords

DEFERIPRONE; IBUPROFEN; IDEBENONE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BODY POSTURE; BRAIN LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DENTATE NUCLEUS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; FRIEDREICH ATAXIA; GAIT; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEART HYPERTROPHY; HUMAN; IRON BLOOD LEVEL; IRON STORAGE; LOW DRUG DOSE; MALE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; SCHOOL CHILD; SCORING SYSTEM; SEPTUM PELLUCIDUM; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; ANTIOXIDANTS; BLOOD CELL COUNT; BRAIN CHEMISTRY; CHILD; DRUG THERAPY, COMBINATION; DYSARTHRIA; FEMALE; FRIEDREICH ATAXIA; GAIT DISORDERS, NEUROLOGIC; HEART FUNCTION TESTS; HUMANS; IRON; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MALE; NEUROLOGIC EXAMINATION; OCULOMOTOR MUSCLES; PROSPECTIVE STUDIES; PYRIDONES; SPEECH DISORDERS; UBIQUINONE; YOUNG ADULT;

EID: 79952694447     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-010-0212-7     Document Type: Article

References (43)

1. Chamberlain S, Shaw J, Rowland A, Wallis J, South S, Nakamura Y, et al. Mapping of mutation causing Friedreich's ataxia to human chromosome 9. Nature. 1988;334(6179):248-50.
2. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423-7. (Pubitemid 26089479)
3. Opal P, Y Zoghbi H, Cruse RP. Friedreich ataxia (monograph on the Internet). Uptodate. 2008. Available at: www.uptodate.com. Accessed 21 April 2008
4. Pandolfo M. Friedreich ataxia. Semin Pediatr Neurol. 2003;10(3):163-72. (Pubitemid 37414092)
5. Dutka DP, Donnelly JE, Nihoyannopoulos P, Oakley CM, Nunez DJ. Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Heart. 1999;81(2):141-7. (Pubitemid 29119387)
6. Lodi R, Hart PE, Rajagopalan B, Taylor DJ, Crilley JG, Bradley JL, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol. 2001;49(5):590-6. (Pubitemid 32429786)
7. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, et al. Selective iron chelation in Friedreich ataxia Biological and clinical implications. Blood. 2007;110(1):401-8. (Pubitemid 47026862)
8. Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005;62(4):621-6. (Pubitemid 40489896)
9. Rustin P, Rotig A, Munnich A, Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res. 2002;36(4):467-9. (Pubitemid 35154096)
10. Artuch R, Aracil A, Mas A, Colome C, Rissech M, Monros E, et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics. 2002;33(4):190-3.
11. Pineda M, Arpa J, Montero R, Aracil A, Domínguez F, Galván M, et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol. 2008;12(6):470-5.
12. Ribaï P, Pousset F, Tanguy ML, Rivaud-Pechoux S, Le Ber I, et al. Neurological, cardiological and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow up. Arch Neurol. 2007;64(4):558-64. (Pubitemid 46588346)
13. Hausse AO, Aggoun Y, Bonnet D, Sidi D, Munnich A, Rötig A, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart. 2002;87(4):346-9. (Pubitemid 34270947)
14. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2003;60(10):1676-9. (Pubitemid 36618100)
15. Rustin P, Bonnet D, Rötig A, Munnich A, Sidi D. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2004;62(3):524-5.
16. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich ataxia: a randomized, placebo-controlled trial. Lancet Neurol. 2007;6(10):878-86. (Pubitemid 47404985)
17. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, Taroni F, et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet. 1999;8(3):425-30. (Pubitemid 29097330)
18. Richardson DR, Mouralian C, Ponka P, Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta. 2001;1536(2-3):133-40. (Pubitemid 32530812)
19. Richardson DR. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Investig Drugs. 2003;12(2):235-45.
20. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97(3):792-8. (Pubitemid 32113415)
21. Waldmeier PC, Buchle AM, Steulet AF. Inhibition of catechol- Omethyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1, 2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol. 1993;45(12):2417-24.
22. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195-203.
23. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106(9):3242-50. (Pubitemid 41565925)
24. Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood. 2008;111(3):1690-9. (Pubitemid 351213461)
25. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood. 2008;112(13):5219-27.
26. Hershko CM, Link GM, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol Rep. 2005;4(2):110-6.
27. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305-12. (Pubitemid 30143646)
28. Ceci A, Baiardi P, FelisiM, CappelliniMD, Carnelli V, De Sanctis V, et al. The 29 safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118(1):330-6. (Pubitemid 34779559)
29. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, et al. Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron chelators. Br J Haematol. 1995;91(1):224-9.
30. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci. 1997;145(2):205-11.
31. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedreich's ataxia. Ann Neurol. 1999;46(1):123-5. (Pubitemid 29314392)
32. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg Rj, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging. 2005;23(1):1-25. (Pubitemid 40269946)
33. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed. 2004;17(7):433-45.
34. Artuch R, Colomé C, Vilaseca MA, Aracil A, Pineda M. Monitoring of idebenone treatment in patients with Friedreich's ataxia by high-pressure liquid chromatography with electrochemical detection. J Neurosci Methods. 2002;115(1):63-6. (Pubitemid 34202278)
35. Schulz JB, Di Prospero NA, Fischbeck K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol. 2009;256 Suppl 1:42-5.
36. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol. 2007;62(5):521-4. (Pubitemid 350308777)
37. Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord. 2008;23(13):1940-4.
38. Marmolino D, Manto M, Acquaviva F, Vergara P, Ravella A, Monticelli A, et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia. PLoS One. 2010;5(4):e10025.
39. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006;2(10):551-8. (Pubitemid 44413238)
40. Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, Rusche JR, et al. Chemical probes identify a role for histone deacetylase three in Friedreich's ataxia gene silencing. Chem Biol. 2009;16(9):980-9.
41. Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry. 2007;78(4):411-3. (Pubitemid 46580555)
42. Meyer C, Schmid G, Görlitz S, Ernst M, Wilkens C, Wilhelms I, et al. Cardiomyopathy in Friedreich's ataxia - assessment by cardiac MRI. Mov Disord. 2007;22(11):1615-22. (Pubitemid 47477924)
43. Goncalves S, Paupe V, Dassa EP, Rustin P. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment. BMC Neurol. 2008;8:20.